Review Article

Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease

Authors: Qi Mao1, Wang-zhi Qin1, Ao Zhang2,3,4, Na Ye1
1 Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China
2 CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica (SIMM), Shanghai 201203, China
3 School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
4 University of Chinese Academy of Sciences, Beijing 100049, China
Correspondence to: Na Ye: yena@suda.edu.cn,
DOI: 10.1038/s41401-020-0365-y
Received: 31 October 2019
Accepted: 13 January 2020
Advance online: 28 February 2020

Abstract

Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease worldwide. However, there is no available therapy reversing the neurodegenerative process of PD. Based on the loss of dopamine or dopaminergic dysfunction in PD patients, most of the current therapies focus on symptomatic relief to improve patient quality of life. As dopamine replacement treatment remains the most effective symptomatic pharmacotherapy for PD, herein we provide an overview of the current pharmacotherapies, summarize the clinical development status of novel dopaminergic agents, and highlight the challenge and opportunity of emerging preclinical dopaminergic approaches aimed at managing the features and progression of PD.
Keywords: Parkinson’s disease; dopamine; D1 receptor; D2 receptor; allosteric modulator; neuroprotection; multitarget; drug discovery and development; neurodegenerative diseases

Article Options

Download Citation

Cited times in Scopus